May 17, 2020

Pivot Health launches new platform to support health professionals

Catherine Sturman
2 min
Digital healthcare is taking off at an exponential rate, with many tech companies moving into the healthcare space. However, traditional challenges stil...

Digital healthcare is taking off at an exponential rate, with many tech companies moving into the healthcare space. However, traditional challenges still remain a bottleneck for many acute settings, such as constant job shortages in specialist and general roles, in which it can take months to recruit a qualified and experienced candidate.

Enter Pivot Health. Based in Seattle, the company has created a new digital platform, where health professionals can place all their details and have their specifications matched up to potential employers looking to fill a new or existing role.

The cloud based platform also garners a person’s characteristics and values, ensuring that the individual is a good fit in both skill and attitude, improving and reducing any potential skill gaps.

Related stories

Simon Frey, Pivot’s co-founder explained to GeekWire: “Healthcare is the fastest-growing labour market in the US and also the most inefficient. On average, it takes about four months for a clinician to change jobs or for a hospital to hire talent, and every additional day that stems from that inefficient process contributes to higher admin costs, lower reimbursements for the hospital and, most importantly, it contributes to worse patient and medical outcomes.”

Founded by a number of healthcare professionals in a multitude of settings, the platform also provides educational opportunities by opening doors for those who wish to enhance or improve their current skills, and also reduces the recruitment time for employers.

Utilising machine algorithms, Frey added: “It’s a two-sided hiring solution. The technology takes into account work-life balance, salary requirements, specialties and many other factors when matching employees with employers.”

The company hopes to expand across the US in upcoming months, and if successful, possibly move to a paid subscription model.

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article